Beta 2 agonists and asthma.
作者信息
Rees J
出版信息
BMJ. 1991 May 18;302(6786):1166-7. doi: 10.1136/bmj.302.6786.1166.
Abstract
摘要
相似文献
1
Beta 2 agonists and asthma.β2 激动剂与哮喘
BMJ. 1991 May 18;302(6786):1166-7. doi: 10.1136/bmj.302.6786.1166.
2
Safety of long-acting beta-agonists--an urgent need to clear the air.长效β受体激动剂的安全性——亟待澄清事实
N Engl J Med. 2005 Dec 22;353(25):2637-9. doi: 10.1056/NEJMp058299.
3
Long-acting beta agonists in asthma therapy.长效β受体激动剂在哮喘治疗中的应用
Curr Allergy Asthma Rep. 2004 Mar;4(2):91-2. doi: 10.1007/s11882-004-0049-6.
4
Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.吸入性皮质类固醇或长效β-激动剂单独或固定剂量联合治疗哮喘：氟替卡松/布地奈德和福莫特罗/沙美特罗的系统评价。
Clin Ther. 2009 Dec;31(12):2779-803. doi: 10.1016/j.clinthera.2009.12.021.
5
Pharmacogenetics of beta(2)-agonists in children.儿童β₂受体激动剂的药物遗传学
J Allergy Clin Immunol. 2009 Dec;124(6):1195-6. doi: 10.1016/j.jaci.2009.09.023.
6
Are there any detrimental effects of the use of inhaled long-acting beta 2-agonists in the treatment of asthma?吸入长效β2受体激动剂用于治疗哮喘有哪些不良影响？
Chest. 1995 Apr;107(4):1116-24. doi: 10.1378/chest.107.4.1116.
7
Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients.福莫特罗而非沙美特罗对两名哮喘患者的支气管扩张作用。
Respiration. 2000;67(1):112-3. doi: 10.1159/000029476.
8
The challenge of long-acting beta-adrenoceptor agonists.长效β-肾上腺素能受体激动剂的挑战。
Respir Med. 1991 Jan;85(1):5-9. doi: 10.1016/s0954-6111(06)80203-9.
9
Long-acting beta(2)-agonists in childhood asthma: Don't change a winning team (yet).长效β₂受体激动剂用于儿童哮喘：（目前）勿改成功之法。
Pediatr Pulmonol. 2000 Mar;29(3):169-71. doi: 10.1002/(sici)1099-0496(200003)29:3<169::aid-ppul2>3.0.co;2-0.
10
Long acting beta 2 agonists and the risk of life threatening asthma.长效β2激动剂与危及生命的哮喘风险
Thorax. 1998 Jan;53(1):1-2. doi: 10.1136/thx.53.1.1.
引用本文的文献
1
The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy.作为有效性综合指标的无发作天数：福莫特罗与沙丁胺醇治疗哮喘的经济学评估示例
Pharmacoeconomics. 1993 Nov;4(5):345-52. doi: 10.2165/00019053-199304050-00005.
2
Long- versus short-acting beta 2-agonists. Implications for drug therapy.长效与短效β2受体激动剂。对药物治疗的影响。
Drugs. 1994 Feb;47(2):207-22. doi: 10.2165/00003495-199447020-00001.
3
Strategy for asthma.哮喘治疗策略
BMJ. 1991 Sep 7;303(6802):571-3. doi: 10.1136/bmj.303.6802.571.
4
Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.福莫特罗。其药理学特性及在可逆性阻塞性气道疾病中的治疗潜力综述。
Drugs. 1991 Jul;42(1):115-37. doi: 10.2165/00003495-199142010-00007.
5
Beta 2 agonists and asthma.β2 激动剂与哮喘
BMJ. 1991 Jul 13;303(6794):123. doi: 10.1136/bmj.303.6794.123.
6
The epidemiology and therapy of airflow limitation in the elderly.老年人气流受限的流行病学与治疗
Drugs Aging. 1992 Nov-Dec;2(6):546-59. doi: 10.2165/00002512-199202060-00009.
7
Future developments in the pharmacotherapy of lung disease.
Pharm Weekbl Sci. 1992 Aug 21;14(4A):221-3. doi: 10.1007/BF01962543.
8
A drug use review study in patients with obstructive lung disease. Assessment of the quality of drug therapy.一项针对阻塞性肺病患者的药物使用回顾性研究。药物治疗质量评估。
Pharm Weekbl Sci. 1992 Oct 16;14(5):311-5. doi: 10.1007/BF01977619.
本文引用的文献
1
Cloning and expression of cDNA encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation.编码牛肾上腺甾体21-羟化特异性细胞色素P-450的cDNA的克隆与表达。
Proc Natl Acad Sci U S A. 1984 Apr;81(7):1986-90. doi: 10.1073/pnas.81.7.1986.
2
Histamine release in vitro: inhibition by catecholamines and methylxanthines.体外组胺释放：儿茶酚胺和甲基黄嘌呤的抑制作用
Science. 1968 Aug 30;161(3844):902-3. doi: 10.1126/science.161.3844.902.
3
Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline.过敏性哮喘患者使用抗哮喘药物治疗4周后支气管高反应性的变化：布地奈德与特布他林的比较
J Allergy Clin Immunol. 1985 Oct;76(4):628-36. doi: 10.1016/0091-6749(85)90786-9.
4
Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma.吸入性糖皮质激素和β-受体激动剂长期治疗对哮喘儿童支气管反应性的影响。
J Allergy Clin Immunol. 1987 Apr;79(4):653-9. doi: 10.1016/s0091-6749(87)80163-x.
5
Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline.吸入特布他林治疗后支气管反应性的反跳性增加。
Lancet. 1988 Mar 12;1(8585):554-8. doi: 10.1016/s0140-6736(88)91352-9.
6
Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study.1981 - 1983年新西兰使用处方非诺特罗与哮喘死亡情况：病例对照研究
Lancet. 1989 Apr 29;1(8644):917-22. doi: 10.1016/s0140-6736(89)92505-1.
7
Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol.抗过敏药物和沙丁胺醇对人分散肺肥大细胞中IgE依赖性组胺释放的抑制作用。
Br J Pharmacol. 1987 Feb;90(2):421-9. doi: 10.1111/j.1476-5381.1987.tb08972.x.
8
Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81.1977 - 1981年新西兰关于处方用非诺特罗与哮喘死亡的病例对照研究。
Thorax. 1990 Mar;45(3):170-5. doi: 10.1136/thx.45.3.170.
9
Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma.
Lancet. 1990 Dec 8;336(8728):1396-9. doi: 10.1016/0140-6736(90)93099-b.
10
Regular inhaled beta-agonist treatment in bronchial asthma.支气管哮喘的常规吸入β-激动剂治疗
Lancet. 1990 Dec 8;336(8728):1391-6. doi: 10.1016/0140-6736(90)93098-a.
Zotero 插件